Illumina vs Guardant vs Natera: The MRD Market Landscape 2026

LONDON, Friday, June 5, 2026 — Molecular residual disease (MRD) testing has become oncology's most contested arena in 2026. Three companies — Illumina, Guardant Health, and Natera — are racing to define the clinical standard for circulating tumour DNA (ctDNA) monitoring, each deploying distinct technological architectures, regulatory strategies, and commercial partnerships. As the American Society of Clinical Oncology annual meeting in Chicago reshapes the liquid biopsy investment thesis, a platform-by-platform analysis reveals sharply divergent paths to the same destination: replacing imaging and tissue re-biopsy with a blood draw. See also our earlier coverage of Illumina's distributed WGS MRD kit launch for full product detail.

Illumina

Guardant Health

Natera

Key Takeaways

• Illumina's distributed WGS MRD kit — unveiled at ASCO 2026 with Mayo Clinic and Bristol Myers Squibb — reaches 10 parts-per-million sensitivity on NovaSeq, the highest claimed detection threshold of any distributed platform in early access as of June 2026.
• Guardant Health's SHIELD test is the only FDA-approved blood-based colorectal cancer screening test, backed by CMS reimbursement and an 83% sensitivity result from the ECLIPSE pivotal trial, giving it a durable first-mover position in population screening.
• Natera's Signatera holds the largest published clinical evidence base — over 40 peer-reviewed studies — with FDA authorisation spanning colorectal, breast, lung, and bladder cancers, and active commercial partnerships with AstraZeneca and Bristol Myers Squibb.
• All three companies are converging on the adjuvant therapy guidance market, where ctDNA MRD status increasingly determines which patients receive or skip post-surgical chemotherapy.
• The global MRD liquid biopsy market is on track to exceed five billion dollars by 2030 according to analysts cited by Reuters, with reimbursement expansion and FDA validation pathways as the primary value inflection events.

The Three Technology Approaches

Each platform reflects a fundamental architectural choice that shapes its clinical utility, cost, and scalability. Illumina's distributed WGS MRD kit anchors to whole-genome sequencing — a tumour-naïve method that does not require a prior tissue biopsy to configure the assay. The kit, announced on May 28 and validated with clinical research partners in early access, targets 10 parts-per-million sensitivity and 99.5% specificity on NovaSeq. The approach democratises MRD testing by allowing hospital laboratories to run assays on-site rather than shipping samples to a central reference lab. Industry benchmark data cited in the ASCO 2026 abstract supports these analytical performance figures.

Guardant Health takes a hybrid approach. Its flagship Guardant360 panel sequences 74 genes in plasma ctDNA, while the next-generation Infinity platform layers tumour-informed WGS over targeted sequencing to improve sensitivity. The SHIELD colorectal cancer screening test — FDA-approved in July 2024 — uses a different methylation-plus-mutation detection logic tuned for population screening rather than therapy guidance. Guardant's commercial infrastructure, built over a decade of oncology panel testing, gives it a distribution advantage no instrument-based competitor can replicate quickly.

Natera's Signatera is the most clinically adopted tumour-informed assay. It sequences whole-exome DNA from a patient's tumour biopsy to identify up to 16 patient-specific variants, then tracks those exact variants in plasma across serial blood draws. This personalised design delivers sub-0.01% variant allele frequency detection in retrospective series published in the New England Journal of Medicine and Nature Medicine. The trade-off is turnaround time: tumour-informed assays require tissue processing before the plasma assay can be configured, adding one to two weeks versus a tumour-naïve blood draw.

Platform Comparison

FDA Status and Clinical Evidence

Regulatory positioning is the sharpest differentiator among the three companies. Natera leads on breadth: Signatera holds FDA authorisation for colorectal, early-stage breast, muscle-invasive bladder, and non-small cell lung cancers, and is the platform of choice in over 40 interventional and observational trials listed on ClinicalTrials.gov. The depth of published data — including prospective randomised cohorts in colorectal cancer, where MRD negativity predicts chemotherapy-free survival with 98% specificity — is difficult for newer entrants to replicate quickly. The company's investor relations disclosure at ir.natera.com details the ongoing BESPOKE programme across multiple tumour types.

Guardant holds the only outright FDA approval for a blood-based cancer screening test: SHIELD for colorectal cancer. The distinction between a screening test (healthy population) and a monitoring test (diagnosed patients) is important — SHIELD's approval does not transfer to MRD use cases — but the regulatory precedent it establishes, and the CMS coverage it unlocked, significantly de-risk Guardant's pipeline applications. The company's regulatory filings are available through investors.guardanthealth.com. Coverage guidance for ctDNA tests is evolving through the CMS Medicare Coverage Database, where a 2024 LCD expanded liquid biopsy access for advanced solid tumours.

Illumina's WGS MRD kit is currently research-use-only, with FDA submission timelines not yet disclosed. The FDA liquid biopsy regulatory framework requires prospective clinical data across diverse patient populations for a de novo or 510(k) clearance. Illumina has positioned the ASCO 2026 launches as the start of a data generation phase, with global commercial launch targeted for 2027. See our coverage of the Gilead FDA accelerated approval for context on how regulators are approaching novel diagnostic and therapeutic submissions in 2026.

FDA Clearance and Clinical Evidence Matrix

Industry Analysis

The MRD market is not a single contest — it is at least three overlapping markets: post-surgical recurrence monitoring, adjuvant therapy guidance, and population screening. Each company holds a structural advantage in one of them. As reported by AP News and covered across the oncology trade press, the inflection is regulatory: once CMS sets a positive Local Coverage Determination for MRD testing in a given tumour type, commercial adoption accelerates rapidly. Natera has front-run this cycle in colorectal cancer, where BESPOKE CRC data showing ctDNA-guided chemotherapy de-escalation is already influencing National Comprehensive Cancer Network guidelines.

Guardant's partnership portfolio — including its collaboration with AstraZeneca on the MERMAID-2 lung cancer trial — reflects a different commercialisation logic: embedding Guardant360 into pharma-sponsored trials to generate the real-world evidence that drives formulary inclusion and payer coverage. The Financial Times biotechnology desk has tracked how this pharma-partnership model has become standard in the diagnostics sector, with companies like Foundation Medicine and Tempus following similar playbooks. For broader capital market context in the life sciences sector, see our analysis of Alphabet's $84.75 billion equity raise and its implications for health technology infrastructure funding.

Illumina's entry changes the competitive geometry. As the supplier of sequencing instruments to both Guardant and Natera's laboratory partners, Illumina has historically sat upstream of the MRD market. Its move to a branded, distributed MRD kit competes directly with its own customers. Bloomberg healthcare analysis notes that Illumina's instrument installed base — over 22,000 active sequencers worldwide — provides a distribution channel for the MRD kit that neither Guardant nor Natera can replicate. The economics flip: rather than selling reagents to labs, Illumina sells a validated MRD workflow that generates recurring consumable revenue at each patient test. Investor filings are available at investor.illumina.com.

Research into ctDNA clinical utility continues to expand through journals including PubMed and health technology press, with over 2,000 new ctDNA-related publications in 2025 alone according to literature database counts. The volume of evidence being generated in parallel by academic centres, pharma sponsors, and the companies themselves creates a compounding advantage for platforms with established research relationships. For comparative context on how FDA carve-out strategies are reshaping health technology market entry, see our coverage of the Oura Ring 5 FDA carve-out strategy.

Financial and Market Position 2026

Why This Matters for Oncology Stakeholders

For oncologists, hospital laboratories, and payers, the competitive intensity in MRD diagnostics is broadly positive: it accelerates evidence generation, drives down unit costs, and increases access to technologies previously confined to academic medical centres. The distributor model Illumina is pioneering — validated kits that run on instruments already installed in hospital molecular labs — addresses the centralised laboratory bottleneck that has slowed Signatera and Guardant360 adoption in smaller regional oncology centres.

For investors, the divergent growth trajectories are telling. Natera's 56% revenue growth and near-$24 billion market capitalisation reflect the market's view of a diagnostics company that has cleared regulatory hurdles and is now in commercial execution. Guardant's 31% growth at a $7 billion valuation implies the market is still pricing in execution risk around SHIELD reimbursement scale-up. Illumina's modest 4.2% growth reflects its instrument-cycle business, but the MRD kit strategy, if successful, could add a recurring, high-margin diagnostics revenue layer that instruments alone cannot provide. Current SEC filings for all three companies are accessible via Illumina, Guardant Health, and Natera investor relations pages.

Forward Outlook

The next twelve months will be decisive. Natera's BESPOKE colorectal cancer trial readout is expected to provide the prospective, randomised evidence needed for a binding CMS national coverage determination — an outcome that could trigger a step-change in Signatera test volume. Guardant's Infinity platform, combining tumour-informed and tumour-naïve WGS in a single workflow, is positioned to close Signatera's sensitivity gap while retaining the central-lab scalability of Guardant360. Illumina's global commercial launch of the distributed WGS MRD kit is targeted for 2027, contingent on regulatory submission and early-access data maturation. The three platforms will increasingly be evaluated not just on analytical performance but on total assay economics — cost per reportable result, insurance reimbursement per code, and integration into electronic medical records workflows. Whichever company wins the CMS national coverage determination in the largest indication first will likely define the market architecture for the remainder of the decade.

Disclosure: Financial figures are derived from company investor relations disclosures. Market capitalisation data reflects approximate valuations as of early June 2026. This article is editorial analysis and does not constitute investment advice. Figures not independently audited by Business 2.0 News.